Abiopharma

Mirati Therapeutics Inc (was acquisied by Bristol Myers Squibb (NYSE: BMY) on 23/01/2024) (MRTX) Announces Clinical Trial Update Mirati Therapeutics Inc (was acquisied by Bristol Myers Squibb (NYSE: BMY) on 23/01/2024) (MRTX) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: response, presentation
• Collaboration: Mirati Therapeutics, Inc.
  • targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook. Forward Looking Statements This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation adagrasib (selective KRASG12C inhibitor), sitravatinib (TAM receptor inhibitor), MRTX1719